Ovarian cancer tumor immune profiles associated with intrauterine device and oral contraceptive use

Wentzensen N, Poole EM, Trabert B, White E, Arslan AA, Patel AV, et al. Ovarian cancer risk factors by histologic subtype: an analysis from the Ovarian Cancer Cohort Consortium. J Clin Oncol. 2016;34:2888–98.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Havrilesky LJ, Gierisch JM, Moorman PG, Coeytaux RR, Urrutia RP, Lowery WJ, et al. Oral contraceptive use for the primary prevention of ovarian cancer. Evid Rep/Technol Assess. 2013;212:1–514.

Google Scholar 

IOM (Institute of Medicine). Clinical preventive services for women: closing the gaps. The National Academies Press, Washington, DC; 2011.

Wheeler LJ, Desanto K, Teal SB, Sheeder J, Guntupalli SR. Intrauterine device use and ovarian cancer risk: a systematic review and meta-analysis. Obstet Gynecol. 2019;134:791–800.

Article 
CAS 
PubMed 

Google Scholar 

Jareid M, Thalabard JC, Aarflot M, Bøvelstad HM, Lund E, Braaten T. Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study. Gynecol Oncol. 2018;149:127–32.

Article 
CAS 
PubMed 

Google Scholar 

Shu XO, Brinton LA, Gao YT, Yuan JM. Population-based case-control study of ovarian cancer in Shanghai. Cancer Res. 1989;49:3670–4.

CAS 
PubMed 

Google Scholar 

Hathaway CA, Conejo-Garcia JR, Fridley BL, Rosner B, Saeed-Vafa D, Moran Segura C, et al. Measurement of ovarian tumor immune profiles by multiplex immunohistochemistry: implications for epidemiologic studies. Cancer Epidemiol Biomark Prev. 2023;32:848–53.

Article 
CAS 

Google Scholar 

Ortiz ME, Croxatto HB. Copper-T intrauterine device and levonorgestrel intrauterine system: biological bases of their mechanism of action. Contraception. 2007;75:S16–30.

Article 
CAS 
PubMed 

Google Scholar 

Cortessis VK, Barrett M, Brown Wade N, Enebish T, Perrigo JL, Tobin J, et al. Intrauterine device use and cervical cancer risk: a systematic review and meta-analysis. Obstet Gynecol. 2017;130:1226–36.

Article 
PubMed 

Google Scholar 

Parazzini F, La Vecchia C, Moroni S. Intrauterine device use and risk of endometrial cancer. Br J Cancer. 1994;70:672–3.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Castellsagué X, Thompson WD, Dubrow R. Intra-uterine contraception and the risk of endometrial cancer. Int J Cancer. 1993;54:911–6.

Article 
PubMed 

Google Scholar 

Myatt L, Elder MG, Chaudhuri G, Lim L. The rat uterine oestrogen receptor in relation to intra-uterine devices and the oestrous cycle [proceedings]. Biochem. Soc Trans. 1977;5:1563–4.

Article 
CAS 
PubMed 

Google Scholar 

Mongiovi JM, Babic A, Sasamoto N, Shafrir AL, Huang T, Townsend MK, et al. Associations between common contraceptive use and circulating inflammatory biomarkers. Am J Epidemiol. 2024;194:85–94.

Zeng F, Wei H, Yeoh E, Zhang Z, Ren ZF, Colditz GA, et al. Inflammatory markers of CRP, IL6, TNFalpha, and soluble TNFR2 and the risk of ovarian cancer: a meta-analysis of prospective studies. Cancer Epidemiol Biomark Prev. 2016;25:1231–9.

Article 
CAS 

Google Scholar 

Shaarawy M, Naguib YA, El Safory LS, Abdel Kader MM. Reactive protein and immunoglobulin levels in women using intrauterine devices. Int J Gynaecol Obstet. 1981;19:125–31.

Article 
CAS 
PubMed 

Google Scholar 

Wiedermann D, Kríz J, Cídl K. Specific serum protein levels in women using intrauterine contraceptive device. Czech Med. 1980;3:239–47.

CAS 
PubMed 

Google Scholar 

Schildkraut JM, Alberg AJ, Bandera EV, Barnholtz-Sloan J, Bondy M, Cote ML, et al. A multi-center population-based case-control study of ovarian cancer in African-American women: the African American Cancer Epidemiology Study (AACES). BMC Cancer. 2014;14:688.

Article 
PubMed 
PubMed Central 

Google Scholar 

Hankey BF, Ries LA, Edwards BK. The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomark Prev. 1999;8:1117–21.

CAS 

Google Scholar 

Bodelon C, Cushing-Haugen KL, Wicklund KG, Doherty JA, Rossing MA. Sun exposure and risk of epithelial ovarian cancer. Cancer Causes Control. 2012;23:1985–94.

PubMed 
PubMed Central 

Google Scholar 

Lo-Ciganic WH, Zgibor JC, Bunker CH, Moysich KB, Edwards RP, Ness RB. Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, or acetaminophen and risk of ovarian cancer. Epidemiology. 2012;23:311–9.

Article 
PubMed 
PubMed Central 

Google Scholar 

Terry KL, De Vivo I, Titus-Ernstoff L, Shih MC, Cramer DW. Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk. Cancer Res. 2005;65:5974–81.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Colditz GA, Hankinson SE. The Nurses’ Health Study: lifestyle and health among women. Nat Rev Cancer. 2005;5:388–96.

Article 
CAS 
PubMed 

Google Scholar 

Troy LM, Michels KB, Hunter DJ, Spiegelman D, Manson JE, Colditz GA, et al. Self-reported birthweight and history of having been breastfed among younger women: an assessment of validity. Int J Epidemiol. 1996;25:122–7.

Article 
CAS 
PubMed 

Google Scholar 

Stampfer MJ, Willett WC, Speizer FE, Dysert DC, Lipnick R, Rosner B, et al. Test of the National Death Index. Am J Epidemiol. 1984;119:837–9.

Article 
CAS 
PubMed 

Google Scholar 

Schildkraut JM, Johnson C, Dempsey LF, Qin B, Terry P, Akonde M, et al. Survival of epithelial ovarian cancer in Black women: a society to cell approach in the African American cancer epidemiology study (AACES). Cancer Causes Control. 2023;34:251–65.

PubMed 

Google Scholar 

Peres LC, Cushing-Haugen KL, Anglesio M, Wicklund K, Bentley R, Berchuck A, et al. Histotype classification of ovarian carcinoma: a comparison of approaches. Gynecol Oncol. 2018;151:53–60.

Article 
PubMed 
PubMed Central 

Google Scholar 

Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, et al. Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. JAMA Oncol. 2017;3:e173290.

Article 
PubMed 
PubMed Central 

Google Scholar 

Harris HR, Rice MS, Shafrir AL, Poole EM, Gupta M, Hecht JL, et al. Lifestyle and reproductive factors and ovarian cancer risk by p53 and MAPK expression. Cancer Epidemiol Biomark Prev. 2018;27:96–102.

Article 
CAS 

Google Scholar 

Shafrir AL, Rice MS, Gupta M, Terry KL, Rosner BA, Tamimi RM, et al. The association between reproductive and hormonal factors and ovarian cancer by estrogen-α and progesterone receptor status. Gynecol Oncol. 2016;143:628–35.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Barnard ME, Hecht JL, Rice MS, Gupta M, Harris HR, Eliassen AH, et al. Anti-inflammatory drug use and ovarian cancer risk by COX1/COX2 expression and infiltration of tumor-associated macrophages. Cancer Epidemiol Biomark Prev. 2018;27:1509–17.

Article 
CAS 

Google Scholar 

Mongiovi JM, Townsend MK, Vitonis AF, Harris HR, Doherty JA, Babic A, et al. Associations between parity, history of breastfeeding, and t-cell profile of ovarian tumors. Cancer Epidemiol Biomark Prev. 2025;34:550–9.

Article 
CAS 

Google Scholar 

Hathaway CA, Townsend MK, Conejo-Garcia JR, Fridley BL, Moran Segura C, Nguyen JV, et al. The relationship of lifetime history of depression on the ovarian tumor immune microenvironment. Brain Behav, Immun. 2023;114:52–60.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Wilson CM, Ospina OE, Townsend MK, Nguyen J, Moran Segura C, Schildkraut JM, et al. Challenges and opportunities in the statistical analysis of multiplex immunofluorescence data. Cancers. 2021;13:3031.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Stanford JB, Mikolajczyk RT. Mechanisms of action of intrauterine devices: update and estimation of postfertilization effects. Am J Obstet Gynecol. 2002;187:1699–708.

Article 
PubMed 

Google Scholar 

Mishell DR Jr. Intrauterine devices: mechanisms of action, safety, and efficacy. Contraception. 1998;58:45S–53S.

Article 
PubMed 

Google Scholar 

Wollen AL, Sandvei R, Mork S, Marandon JL, Matre R. In situ characterization of leukocytes in the fallopian tube in women with or without an intrauterine contraceptive device. Acta Obstet Gynecol Scand. 1994;73:103–12.

Article 
CAS 
PubMed 

Google Scholar 

Tursi A, Mastrorilli A, Ribatti D, Loiudice L, Contino R, Claudatus J. Possible role of mast cells in the mechanism of action of intrauterine contraceptive devices. Am J Obstet Gynecol. 1984;148:1064–6.

Article 
CAS 
PubMed 

Google Scholar 

Randić L, Haller H, Suśa M, Rukavina D. Cells adherent to copper-bearing intrauterine contraceptive devices determined by monoclonal antibodies. Contraception. 1990;42:35–42.

Article 
PubMed 

Google Scholar 

Serrano MG, Edwards D, Ahmed K, Bailey VC, Beksinska M, Edupuganti L, et al. Effect of contraceptive methods on the vaginal microbiome and host immune factors. Contraception. 2025;148:110936.

Radzey N, Harryparsad R, Meyer B, Chen PL, Gao X, Morrison C, et al. Genital inflammatory status and the innate immune response to contraceptive initiation. Am J Reprod Immunol. 2022;88:e13542.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Kim CR, Martinez-Maza O, Magpantay L, Magyar C, Gornbein J, Rible R, et al. Immunologic evaluation of the endometrium with a levonorgestrel intrauterine device in solid organ transplant women and healthy controls. Contraception. 2016;94:534–40.

Article 
CAS 
PubMed 

Google Scholar 

Fang L, Liu K, Liu C, Wang X, Ma W, Xu W, et al. Tumor accomplice: T cell exhaustion induced by chronic inflammation. Front Immunol. 2022;13:979116.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Savant SS, Sriramkumar S, O’Hagan HM. The role of inflammation and inflammatory mediators in the development, progression, metastasis, and chemoresistance of epithelial ovarian cancer. Cancers. 2018;10:251.

Article 
PubMed 
PubMed Central 

Google Scholar 

Moldenhauer LM, Jin M, Wilson JJ, Green ES, Sharkey DJ, Salkeld MD, et al. Regulatory T cell proportion and phenotype are altered in women using oral contraception. Endocrinology. 2022;163:bqac098.

Article 
PubMed 
PubMed Central 

Google Scholar 

Auerbach L, Hafner T, Huber JC, Panzer S. Influence of low-dose oral contraception on peripheral blood lymphocyte subsets at particular phases of the hormonal cycle. Fertil Steril. 2002;78:83–9.

Article 
PubMed 

Google Scholar 

Huang T, Shafrir AL, Eliassen AH, Rexrode KM, Tworoger SS. Estimated number of lifetime ovulatory years and its determinants in relation to levels of circulating inflammatory biomarkers. Am J Epidemiol. 2020;189:660–70.

Article 
PubMed 
PubMed Central 

Google Scholar 

Wang Q, Würtz P, Auro K, Morin-Papunen L, Kangas AJ, Soininen P, et al. Effects of hormonal contraception on systemic metabolism: cross-sectional and longitudinal evidence. Int J Epidemiol. 2016;45:1445–57.

Article 
PubMed 
PubMed Central 

Google Scholar 

Divani AA, Luo X, Datta YH, Flaherty JD, Panoskaltsis-Mortari A. Effect of oral and vaginal hormonal contraceptives on inflammatory blood biomarkers. Mediat Inflamm. 2015;2015:379501.

Article 

Google Scholar 

Piltonen T, Puurunen J, Hedberg P, Ruokonen A, Mutt SJ, Herzig KH, et al. Oral, transdermal and vaginal combined contraceptives induce an increase in markers of chronic inflammation and impair insulin sensitivity in young healthy normal-weight women: a randomized study. Hum Reprod. 2012;27:3046–56.

Article 
CAS 
PubMed 

Google Scholar 

Cauci S, Di Santolo M, Culhane JF, Stel G, Gonano F, Guaschino S. Effects of third-generation oral contraceptives on high-sensitivity C-reactive protein and homocysteine in young women. Obstet Gynecol. 2008;111:857–64.

Article 
CAS 
PubMed 

Google Scholar 

Wang D, DuBois RN. Immunosuppression associated with chronic inflammation in the tumor microenvironment. Carcinogenesis. 2015;36:1085–93.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41:49–61.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Savage PA, Malchow S, Leventhal DS. Basic principles of tumor-associated regulatory T cell biology. Trends Immunol. 2013;34:33–40.

Article 
CAS 
PubMed 

Google Scholar 

Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12:253–68.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Park H. Association between oral contraceptive use and the high-sensitivity C-reactive protein level in premenopausal Korean women. Healthcare. 2022;10:361.

Article 
PubMed 
PubMed Central 

Google Scholar 

van Rooijen M, Hansson LO, Frostegård J, Silveira A, Hamsten A, Bremme K. Treatment with combined oral contraceptives induces a rise in serum C-reactive protein in the absence of a general inflammatory response. J Thromb Haemost. 2006;4:77–82.

Article 
PubMed 

Google Scholar 

Dreon DM, Slavin JL, Phinney SD. Oral contraceptive use and increased plasma concentration of C-reactive protein. Life Sci. 2003;73:1245–52.

Article 
CAS 
PubMed 

Google Scholar 

Trabert B, Tworoger SS, O’Brien KM, Townsend MK, Fortner RT, Iversen ES, et al. The risk of ovarian cancer increases with an increase in the lifetime number of ovulatory cycles: an analysis from the Ovarian Cancer Cohort Consortium (OC3). Cancer Res. 2020;80:1210–8.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Michels KA, Pfeiffer RM, Brinton LA, Trabert B. Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, breast, and colorectal cancers. JAMA Oncol. 2018;4:516–21.

Article 
PubMed 
PubMed Central 

Google Scholar